Virbac

Animal Parasiticides Market is Anticipated to Reach USD 15.6 billion, at a CAGR of 5.7% CAGR by 2031 - Report by Transparency Market Research Inc.

Retrieved on: 
Tuesday, December 12, 2023
Merck & Co., Research, Safety, Pig, Urbanization, Boehringer Ingelheim, Bayer, Virbac, Research report, Animal, Parasitism, Merck, Zoonosis, Probiotic, Nanotechnology, Growth, Knowledge, Livestock, Poultry, Cattle, Pet industry, Agriculture, Fine chemical, Elanco

WILMINGTON, Del., Dec. 12, 2023 /PRNewswire/ -- The global animal parasiticides market is estimated to flourish at a CAGR of 5.7% from 2023 to 2031. According to Transparency Market Research, sales of animal parasiticides are slated to total US$ 15.6 billion by the end of the aforementioned period of assessment.

Key Points: 
  • Growing urbanization, rising disposable income, and improved awareness about animal health amplify the demand for effective parasiticides.
  • Spot-on treatments and oral tablets dominate the animal parasiticides market, offering efficient and convenient solutions for parasite control in animals.
  • Food-producing animals, particularly cattle, poultry, and swine, lead the animal parasiticides market due to their extensive agricultural significance.
  • North America leads the animal parasiticides market due to advanced research, stringent regulations, and robust veterinary healthcare infrastructure.

Animal Parasiticides Market is Anticipated to Reach USD 15.6 billion, at a CAGR of 5.7% CAGR by 2031 - Report by Transparency Market Research Inc.

Retrieved on: 
Tuesday, December 12, 2023
Merck & Co., Research, Safety, Pig, Urbanization, Boehringer Ingelheim, Bayer, Virbac, Research report, Animal, Parasitism, Merck, Zoonosis, Probiotic, Nanotechnology, Growth, Knowledge, Livestock, Poultry, Cattle, Pet industry, Agriculture, Fine chemical, Elanco

WILMINGTON, Del., Dec. 12, 2023 /PRNewswire/ -- The global animal parasiticides market is estimated to flourish at a CAGR of 5.7% from 2023 to 2031. According to Transparency Market Research, sales of animal parasiticides are slated to total US$ 15.6 billion by the end of the aforementioned period of assessment.

Key Points: 
  • Growing urbanization, rising disposable income, and improved awareness about animal health amplify the demand for effective parasiticides.
  • Spot-on treatments and oral tablets dominate the animal parasiticides market, offering efficient and convenient solutions for parasite control in animals.
  • Food-producing animals, particularly cattle, poultry, and swine, lead the animal parasiticides market due to their extensive agricultural significance.
  • North America leads the animal parasiticides market due to advanced research, stringent regulations, and robust veterinary healthcare infrastructure.

Spay and Neuter Market Expected to Reach $2.24 Billion in 2023 with 5.8% CAGR: A Growing Trend in Pet Ownership Drives Demand

Retrieved on: 
Thursday, October 12, 2023
Ethos, Benchmark, HPM, Anicura, COVID-19, Hospital, Agriculture, Customer insight, Cat, Uterus, Global Insight, Country, Animal, Tubing (recreation), Pet, VCA Animal Hospitals, Growth, Virbac, Dog, Reproduction, Hysterectomy, Orchiectomy, Pet industry, Veterinary medicine, Cryptocurrency, Retail, Video game, Birth control

DUBLIN, Oct. 12, 2023 /PRNewswire/ -- The "Spay And Neuter Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 12, 2023 /PRNewswire/ -- The "Spay And Neuter Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • This growth is poised to continue, with the spay and neuter market anticipated to reach $2.6 billion in 2027, sustaining a CAGR of 4.7%.
  • The spay and neuter market research report offers comprehensive statistics, including global market size, regional shares, and competitor insights.
  • The growing trend of pet adoption is expected to drive spay and neuter market growth.

Global Veterinary Biomarkers Market Size/Share Envisaged to Reach USD 2,554.79 Million By 2032, at CAGR 12.3%: Polaris Market Research

Retrieved on: 
Thursday, August 31, 2023
Urbanization, American Veterinary Medical Association, Laboratory, Human, Animal, Pet, Prevalence, AVMA, Veterinarian, Cancer, Livestock, Research, Infection, American Kennel Club, Biomarker, Product type, Element, USD, Government, Detail, HIV disease progression rates, American Pet Products Association, Dog, Government agency, Cattle, Growth, Diagnosis, AKC, Disease, Idexx Laboratories, Cat, Geography, Pharmaceutical industry, Online shopping, Pet industry, Medical imaging, Vaccine, Veterinary medicine, Zoetis, Application, Merck, Virbac

Explore customized purchase options

Key Points: 
  • Explore customized purchase options
    R&D by companies: Rising emphasis on increasing research and development activities by leading companies to improve biomarker portfolios is fueling the veterinary biomarkers market growth.
  • Also, the rising trend of adopting pets from shelters and rescue organizations is boosting the veterinary biomarkers market growth.
  • Cases of cancer and cardiovascular diseases: Veterinary biomarkers are used in veterinary applications to detect and diagnose diseases in the initial stages.
  • Polaris Market Research has segmented the veterinary biomarkers market report based on animal type, product type, application, disease type, and region:

Global Veterinary Vaccines Market 2023-2029: Merck & Co. Dominates the Competition, Closely Followed by Boehringer Ingelheim, Ceva Sante Animale, and Zoetis

Retrieved on: 
Wednesday, August 23, 2023
Benchmark, Vaccine, Antigen, Partnership, Vaccination, Marketing, Veterinarian, Aquaculture, Livestock, Infection, Uniloc USA, Inc. v. Microsoft Corp., Iowa State University, Infant, Compound annual growth rate, Schering-Plough, Air Liquide, Ceva, Acquisition, Animal, Artemis Technologies, Dog, Cattle, Rabbit, Growth, Merck, Merck & Co., Enrofloxacin, Health, Pig, Virbac, Disease, Boehringer Ingelheim Animal Health, Bordetella bronchiseptica, Cat, Fine chemical, Pharmaceutical industry, Pet

To maintain a competitive edge and meet changing demands, market participants are employing various strategies, such as acquisitions and partnerships.

Key Points: 
  • To maintain a competitive edge and meet changing demands, market participants are employing various strategies, such as acquisitions and partnerships.
  • In terms of market competition, Merck & Co., Inc. emerged as a forerunner in the market, closely followed by companies like Boehringer Ingelheim International GmbH, Ceva Sante Animale, and Zoetis Inc.
  • Apr-2022: Ceva Sante Animale signed an agreement with Mitsui & Co., Ltd., a Japan-based investment, and trading company to form Ceva Bussan Animal Health K.K.
  • This Joint venture aims to boost the broadening of the veterinary laboratory to Japan, a critical market for the business.

Animal Parasiticides Market worth $14.1 billion | MarketsandMarkets

Retrieved on: 
Tuesday, March 28, 2023
SME, Human, Boehringer Ingelheim, Farmer, USFDA, Sarolaner, Afoxolaner, EMA, Tablet, Animal, Soil, Investment, Water, Porter's five forces analysis, Cattle, Parasitism, Cat, Merck & Co., Enrofloxacin, Health, Pig, European Commission, Safety, Pharmaceutical industry, Livestock, Norbrook, Virbac

Increased animal health and production: Parasiticides are highly effective in controlling parasites and can help to improve an animals' health and production.

Key Points: 
  • Increased animal health and production: Parasiticides are highly effective in controlling parasites and can help to improve an animals' health and production.
  • Increased market access: Parasiticides can help to open up new markets for animals and their products, allowing farmers to expand their business.
  • Animal Parasiticides Market - Report Highlights:
    The current edition of the report consists of an updated market overview.
  • Additional points in the market overview have been added, keeping in mind the impact of Recession impact on the overall animal parasiticides market.

Animal Parasiticides Market worth $14.1 billion | MarketsandMarkets

Retrieved on: 
Tuesday, March 28, 2023
SME, Human, Boehringer Ingelheim, Farmer, USFDA, Sarolaner, Afoxolaner, EMA, Tablet, Animal, Soil, Investment, Water, Porter's five forces analysis, Cattle, Parasitism, Cat, Merck & Co., Enrofloxacin, Health, Pig, European Commission, Safety, Pharmaceutical industry, Livestock, Norbrook, Virbac

Increased animal health and production: Parasiticides are highly effective in controlling parasites and can help to improve an animals' health and production.

Key Points: 
  • Increased animal health and production: Parasiticides are highly effective in controlling parasites and can help to improve an animals' health and production.
  • Increased market access: Parasiticides can help to open up new markets for animals and their products, allowing farmers to expand their business.
  • Animal Parasiticides Market - Report Highlights:
    The current edition of the report consists of an updated market overview.
  • Additional points in the market overview have been added, keeping in mind the impact of Recession impact on the overall animal parasiticides market.

Flea, Tick, And Heartworm Products Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Thursday, December 22, 2022
EntirelyPets, US, COVID-19, Flea, Animal, Hair, Parasitism, Loneliness, Research, Praziquantel, Dog, Unicharm, Ivermectin, Pyrantel, Exocrine gland, Tick, Skin, Cat, Forecasting, Family, Heart, Growth, Acquisition, Organization, Anthelmintic, Cestoda, Merck, Dermatitis, Eli Lilly and Company, Perrigo, Human, Bayer, Geography, Pet, Dietary supplement, Virbac

The lea, tick, and heartworm products market is expected to reach $3.68 billion in 2026 at a CAGR of 9.4%.

Key Points: 
  • The lea, tick, and heartworm products market is expected to reach $3.68 billion in 2026 at a CAGR of 9.4%.
  • North America was the largest region in the flea, tick, and heartworm products market in 2021.Europe was the second largest region in the flea, tick, and heartworm products market.
  • Product innovation is a key trend gaining popularity in the flea, tick, and heartworm products market.Major companies in the flea, tick, and heartworm products market are advancing in their new technologies and research and developments in the flea, tick, and heartworm products market.
  • The flea, tick, and heartworm products market research report is one of a series of new reports that provides flea, tick, and heartworm products market statistics, including flea, tick, and heartworm products industry global market size, regional shares, competitors with flea, tick, and heartworm products market share, detailed flea, tick, and heartworm products market segments, market trends, and opportunities, and any further data you may need to thrive in the flea, tick, and heartworm products industry.

United States Veterinary Oncology Market Trends/Analysis Report 2022: A $171.16 Million Market by 2030 - Use of Canines as a Model for Clinical Trials by Researchers Aiding Market Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 6, 2022
Health, Oncology, Pets, Consumer, Neoplasm, COVID-19, Cancer, Hemangiosarcoma, Osteosarcoma, Therapy, Government, Awareness, Recurrence, Incidence, Dog, Oregon State University, PETS, Lymphoma, Animal, Prevalence, FDA, CAGR, Virbac, Elanco, Risk, Growth, Drug development, Medical imaging, Vaccine, Pharmaceutical industry, Pet, Radiology, Immunotherapy

The market is expected to expand at a CAGR of 8.7% from 2022 to 2030.

Key Points: 
  • The market is expected to expand at a CAGR of 8.7% from 2022 to 2030.
  • Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.
  • For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors.
  • For instance, in May 2020, PetCure Oncology and Sugar Land Veterinary Specialists publicized a novel radiation oncology service, expanding their network in Houston

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

Retrieved on: 
Sunday, July 24, 2022
Signal transduction, Death, Environment, United Kingdom, Injection, Virbac, Journal of Veterinary Internal Medicine, Human, Sarcoma, PKC, Extremities, Safety, Targeted alpha-particle therapy, Cancer, Recurrence, Tigilanol tiglate, DOI, Patient, Neoplasm, Pharmacokinetics, Animal, EBioMedicine, Wound healing, Pharmaceutical industry, Medical imaging, Vaccine

Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.

Key Points: 
  • Evaluate the degree of tumour ablation in tumours and or tumour segments treated with one or more injections of tigilanol tiglate.
  • QBiotics' lead oncology product, tigilanol tiglate, is a small molecule targeting a range of solid tumours across multiple species.
  • Tigilanol tiglate has a multimodal action that involves injected tumour responses as well as systemic responses in non-injected tumours.
  • Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate.